High-sensitivity cardiac troponin T is associated with cognitive decline in older adults at high cardiovascular risk by Wijsman, Liselotte W. et al.
  
 
 
 
 
Wijsman, L. W. et al. (2016) High-sensitivity cardiac troponin T is associated with 
cognitive decline in older adults at high cardiovascular risk. European Journal of 
Preventive Cardiology, 23(13), pp. 1383-1392. 
 
   
There may be differences between this version and the published version. You are 
advised to consult the publisher’s version if you wish to cite from it. 
 
 
 
 
http://eprints.gla.ac.uk/129586/ 
     
 
 
 
 
 
 
Deposited on: 24 November 2016 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
 1 
High-sensitivity cardiac troponin T is associated with cognitive decline in older 
adults at high cardiovascular risk 
 
Liselotte W. Wijsman, MD1, Anton J.M. de Craen, PhD1, Stella Trompet, PhD1,2, Behnam Sabayan, MD, MSc, PhD1, 3, Majon 
Muller, MD, PhD1, David J. Stott4, Ian Ford5, PhD, Paul Welsh, PhD6, Rudi G.J. Westendorp, MD, PhD1,7, J. Wouter Jukema, 
MD, PhD2, Naveed A. Sattar*, MD, PhD6, Simon P. Mooijaart*, MD, PhD1,8  
 
1 Department of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, the Netherlands  
2 Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands 
3 Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands 
4 Academic Section of Geriatrics, Faculty of Medicine, University of Glasgow, Glasgow, UK 
5 Robertson Center for Biostatistics, University of Glasgow, Glasgow, UK 
6 British Heart Foundation, Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK 
7 Leyden Academy on Vitality and Ageing, Leiden, the Netherlands 
8 Institute for Evidence-Based Medicine in Old age, Leiden, the Netherlands 
*both authors contributed equally 
 
Corresponding author:  
Prof. Naveed A. Sattar, 126 University Place, BHF Glasgow Cardiovascular Research Centre, University of Glasgow,  
Glasgow, G12 8TA 
E-mail: Naveed.Sattar@glasgow.ac.uk 
Words manuscript (body): 3024  Words abstract: 286 Number of tables: 3   
Figures: 2          Supplemental tables: 7 Supplemental figures: 2   
 2 
Abstract  
Aims Cardiac troponin T (cTnT), measured with a high-sensitivity (hs) assay, is associated with cognitive 
decline, but the underlying mechanism is unknown. We investigated the association of hs-cTnT with cognitive 
function and decline, and studied whether this association was independent of cardiovascular diseases or risk 
factors, and N-terminal pro-brain natriuretic peptide (NT-proBNP). 
 
Methods and Results We studied 5407 participants (mean age 75.31 years) from the PROspective Study of 
Pravastatin in the Elderly at Risk, who all had cardiovascular diseases or risk factors thereof. Participants with 
pre-existent advanced clinical heart failure were excluded. Hs-cTnT and NT-proBNP obtained after 6 months of 
follow-up were related with cognitive function, tested repeatedly during a mean follow-up of 3.2 years. 
Participants with higher hs-cTnT performed worse at baseline on Stroop test (mean baseline score (standard 
error (SE)) lowest vs. highest third 65.91 (1.16) vs. 69.40 (1.10) seconds, p<0.001), Letter-Digit Coding test 
(23.35 (0.32) vs. 22.40 (0.31) digits coded, p<0.001), immediate Picture-Word Learning test (9.45 (0.09) vs. 
9.31 (0.08) pictures remembered, p=0.002) and delayed Picture-Word Learning test (10.33 (0.12) vs. 10.10 
(0.12) pictures remembered, p=0.013). Furthermore, participants with higher hs-cTnT had steeper decline on 
Stroop test (mean annual change (SE) lowest vs. highest third 0.34 (0.12) vs. 1.06 (0.12) seconds, p=0.013), 
Letter-Digit Coding test (-0.29 (0.03) vs. -0.46 (0.03) digits coded, p<0.001), immediate Picture-Word Learning 
test (0.01 (0.01) vs. -0.06 (0.01) pictures remembered, p<0.001) and delayed Picture-Word Learning test (-0.03 
(0.01) vs. -0.12 (0.02) pictures remembered, p=0.001). Associations were independent of cardiovascular 
diseases risk factors or apoE genotype. Further adjusting for NT-proBNP levels revealed the same results. 
 
Conclusions Higher levels of hs-cTnT associate with worse cognitive function and steeper cognitive decline in 
older adults independent of cardiovascular diseases, risk factors and NT-proBNP.   
 
 
Keywords cardiac troponin T, cognition, cardiovascular diseases, NT-proBNP
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Introduction 
Cardiac troponin T (cTnT) is a protein that is released in response to cardiomyocyte necrosis, and is routinely 
used in the diagnosis of acute myocardial infarction.(1) In patients with cardiovascular disease, higher levels of 
cTnT, measured with a high-sensitivity (hs) assay, are associated with higher risk of incident coronary heart 
disease, heart failure and stroke.(1, 2) Moreover, in patients free from cardiovascular disease, raised levels of 
hs-cTnT have also been associated with higher risk of all-cause mortality and myocardial infarction.(3)  
 
Cardiovascular diseases are important risk factors for cognitive impairment and dementia.(4) Recent evidence 
shows that in subjects without cardiovascular disease, higher levels of hs-cTnT are associated with silent brain 
infarcts and white matter lesion progression.(5) Hs-cTnT might therefore be a sensitive systemic marker for 
structural brain damage, which is associated with decreased cognitive function and dementia.(6) Hs-cTnT has 
recently also been associated with cognitive function, but the underlying mechanism is unknown.(7) Besides the 
fact that cardiac disease and cognitive dysfunction share common risk factors there may be an alternative 
explanation. Myocardial ischemia or infarction, as detected by increased hs-cTnT, may lead to clinical heart 
failure or decreased cardiac function, which in turn leads to cognitive decline.(8) Given the predicted increase in 
prevalence of cognitive dysfunction in the coming decades, unravelling early predictors of cognitive decline is of 
importance.(9)  
 
The aims of this study were to investigate 1) whether subjects with higher levels of hs-cTnT are at increased risk 
of worse cognitive function and steeper cognitive decline; 2) whether this was independent of cardiovascular 
diseases or its risk factors, and 3) whether this was independent of N-terminal pro-brain natriuretic peptide (NT-
proBNP), a marker used in the diagnosis of clinical heart failure.(10-12) We used data from the PROspective 
Study of Pravastatin in the Elderly at Risk (PROSPER), which included 5804 older men and women who all had 
a cardiovascular disease or cardiovascular risk factors thereof.  
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Methods 
Study design and participants 
Data were obtained from the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER), a 
randomized, double-blind, placebo-controlled trial designed to investigate the effect of pravastatin in prevention 
of vascular events in older individuals with pre-existing cardiovascular disease or risk factors thereof.(13) Briefly, 
main inclusion criteria were that participants had either pre-existing vascular disease (coronary, cerebral or 
peripheral) or an elevated level of developing vascular disease because of smoking, diabetes mellitus or 
hypertension. Furthermore, their total cholesterol level was required to be between 4.0 – 9.0 mmol/L and their 
triglyceride concentration < 6.0 mmol/L. Participants with congestive heart failure, defined as New York Heart 
Association functional class III or IV, were not included in the PROSPER study, nor were participants who were 
previously diagnosed with atrial fibrillation.(13) Furthermore, poor cognitive function at baseline, defined as a 
Mini-Mental Score Examination below 24 points, was an exclusion criteria.  Participants with congestive heart 
failure, defined as New York Heart Association functional class III or IV, were not included in the PROSPER 
study, nor were participants who were previously diagnosed with atrial fibrillation.(13) This trial included 5804 
men and women aged 70-82 years old who were enrolled from three collaborating centers in Ireland, Scotland 
and the Netherlands. Approximately 50% of the participants had cardiovascular disease including stable angina, 
intermittent claudication, stroke, transient ischemic attack, myocardial infarction and/or vascular surgery. The 
rest of participants had one or more cardiovascular risk factor, defined as hypertension, smoking or diabetes 
mellitus. Participants with congestive heart failure, defined as New York Heart Association functional class III or 
IV, were not included in the PROSPER study.(13) The primary outcome of the trial was the combined endpoint 
of definite or suspect death from coronary heart disease, non-fatal myocardial infarction and fatal or non-fatal 
stroke during a mean follow-up period of 3.2 years.(14) The institutional ethics committees of the three 
collaborating centers approved the study and all participants gave written informed consent. 
 
cTnT and NT-proBNP measurements  
cTnT and NT-proBNP were measured in blood samples obtained after 6 months of follow-up in EDTA tubes. 
Both proteins were measured using an electrochemiluminiscence immunoassay on a Roche Modular Analytics 
E170. The Roche cTnT measurement was performed with a high-sensitivity assay, which has a limit of detection 
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of 0.003 ug/L and a 99th percentile cutoff of 0.014 ug/L. Furthermore, the Elecsys Troponin T hs assay used had 
a CV of 10.38% at a cTNT concentration of 0.010 ug/L, thus the assay is able to differentiate reasonably well at 
lower concentrations. For those patients who had a level below the detection limit, we have assumed these 
values to be distributed anywhere between zero and 0.003, of which the average is 0.0015. Hs-cTnT levels 
below detection level were therefore set to 0.0015 ug/L in the statistical analyses. To further investigate whether 
the association of cTnT with cognitive function and decline was independent of clinical heart failure, we studied 
participants with low and high NT-proBNP levels more in detail. To be sure that participants had no clinical heart 
failure, we chose a conservative cut-off of 200 ng/L for NT-proBNP. Furthermore, we stratified our analyses by a 
less conservative cut-off of low (<400 ng/L) and high (≥ 400 ng/L) NT-proBNP, based on relevant guidelines.(15) 
 
Cognitive function 
The MMSE was used to evaluate global cognitive function; participants with a baseline score below 24 points 
were not included in PROSPER.(13) Cognitive function was tested at baseline and at 9, 18, 30 months and at 
the end of the study. The time-point of the measurement at the end of the study varied between 36 and 48 
months; therefore, we performed the analysis with their individually varying time point, but report the results for 
the mean of these time points (at 42 months). Four different neuropsychological tests were used to assess 
executive function, attention, and immediate and delayed memory. The Stroop-Colour-Word-Test was used to 
test selective attention and reaction time. Participants were asked to read a color name which was displayed in 
a color different from the color it actually names. Outcome parameter was the total number of seconds to 
complete the test; a higher score indicates worse performance. Processing speed was tested by the Letter-Digit 
Coding Test. Participants had to match certain digits with letters according to a provided key. Outcome variable 
was the total number of correct entries in 60 seconds, therefore higher scores represented better performance. 
The Picture-Word Learning Test was used to assess immediate and delayed memory. Fifteen pictures were 
presented, and participants were asked to recall as many pictures as possible in three trials. After 20 minutes 
they were asked to repeat the pictures they remembered to measure their delayed recall. Outcome parameter 
was the accumulated number of correct recalled pictures, immediate and after 20 minutes. Higher scores thus 
indicate better performance. A detailed description of the cognitive tests has been published previously.(16) 
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Since treatment with pravastatin did not influence cognitive function during follow-up, we included participants 
from both pravastatin and placebo groups.(17) 
 
Statistical analyses 
We present our results in thirds of cTnT. Baseline characteristics of the study participants are presented as 
mean (standard deviation) for continuous variables and number (percentage) for categorical variables for each 
third of cTnT. Differences in continuous variables were tested with linear regression models; differences in 
categorical variables were tested by Chi-squared tests. Because of the skewed distribution of cTnT levels and 
log-transformed cTnT levels, all analyses were performed using the square root of cTnT, which was normally 
distributed (supplemental figure 2). To investigate the cross-sectional association of cTnT with cognitive 
function, we used linear regression models. The square root levels of cTnT were included as independent 
variable; outcome variable was the mean baseline score on each of the four cognitive function tests. Linear 
mixed models were used to examine the association between cTnT and cognitive decline over time. The models 
included the square root of cTnT level, time (in years) and the interaction term between time and the square root 
of cTnT level.  
 
We performed our analyses according to two different adjustment models. In the first model, we only adjusted 
for the variables age, sex, country, education, treatment group and cognitive test version where appropriate 
(minimally adjusted model). In the second model, we further adjusted for ApoE genotype, history of 
cerebrovascular and cardiovascular disease, history of hypertension, history of diabetes mellitus, current 
smoking, baseline systolic and diastolic blood pressure, high density lipoprotein (HDL) and low density 
lipoprotein (LDL) cholesterol levels, triglycerides, body mass index and estimated glomerular filtration rate 
(eGFR), to investigate the potential influence of these factors on the associations. Since the observed 
associations did not materially differ, we chose to present the results from comprehensive adjusted models. 
Results from minimally adjusted models are included as supplemental material. Concerning the longitudinal 
analyses, we further studied the effects of potential confounders on the slope of the association by additionally 
including the interaction terms between time, square root of troponin level and potential confounder in the linear 
mixed models. These results did not materially affect the slope of the analyses and we therefore present the 
results of the simple models. Finally, to explore the influence of cardiovascular diseases and risk factors in more 
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details, we performed additional analyses in which we stratified for history of cardiovascular diseases and risk 
factors.  
 
To further investigate whether the association of cTnT with cognitive function and decline was independent of 
clinical heart failure, we stratified our analyses by low (<200 ng/L) and high (≥ 200 ng/L) NT-proBNP level and 
calculated a p-value for interaction to test whether the difference was significant. In addition, we 1) further 
adjusted our analyses for continuous levels of NT-proBNP and 2) stratified our analyses by a less conservative 
cut-off of low (<400 ng/L) and high (≥ 400 ng/L) NT-proBNP, was based on relevant guidelines.(15) Moreover, 
we performed additional analyses in which we excluded both participants with heart failure hospitalization during 
follow-up and participants who used loop diuretics at baseline, since those participants are likely to suffer from 
clinical heart failure. Furthermore, we performed several sensitivity analyses in which we separately excluded 
participants who, during follow-up, had 1) a stroke and / or transient ischemic attack (TIA); 2) coronary events; 
3) atrial fibrillation; 4) cardiovascular events; and 5) a sign of previous myocardial infarction (defined as 
pathological Q or QS-waves on their baseline ECG). Finally, we excluded participants with high cTnT levels 
(defined conform 99th percentile as hs-cTnT levels >0.014 μg/L), to investigate the association of normal levels 
of cTnT with cognitive function and decline. 
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Results 
Out of the total number of 5804 PROSPER participants, we excluded n=397 participants with missing cTnT 
measurements. The final sample of the present study included n=5407 participants with a mean (standard 
deviation) age of 75.31 (3.36) years (supplemental figure 1). 
 
Participants with higher cTnT were older, less frequently female and had a higher prevalence of hypertension, 
diabetes mellitus, stroke or transient ischemic attack, myocardial infarction and vascular disease (all p-values 
<0.05) (table 1). No difference in total cholesterol, high-density lipoprotein and low-density lipoprotein levels 
were found between the thirds of cTnT (all p-values >0.05). Systolic and diastolic blood pressure at baseline 
were higher in participants with higher cTnT levels (both p-values <0.001). Furthermore, participants with higher 
cTnT had a lower eGFR and higher NT-proBNP levels (both p-values <0.001). 
 
The association of cTnT with cognitive function at baseline and cognitive decline during follow-up is shown in 
table 2. At baseline, participants with higher cTnT had worse cognitive function on Stroop test, Letter-Digit 
Coding test, immediate Picture-Word Learning test and delayed Picture-Word Learning test (all p-values <0.05). 
Longitudinally, participants with higher cTnT had a steeper decline on Stroop test, Letter-Digit Coding test, 
immediate Picture-Word Learning test and delayed Picture-Word Learning test (all p-values <0.05). Results 
were independent of cardiovascular diseases or risk factors, since all analyses were adjusted for histories of 
cardiovascular diseases and risk factors thereof. Data on the association of cTnT with cognitive function and 
decline from minimally adjusted models did not materially differ from comprehensive adjusted models 
(supplemental table 1). Figure 1 shows the results of the association of cTnT with cognitive decline, stratified by 
cardiovascular diseases and risk factors. Participants with a history of hypertension had a steeper decline on 
Letter-Digit Coding test and immediate Picture-Word Learning test (both p-values for interaction=0.011).  
 
Figure 2 shows the association of cTnT with cognitive function at baseline in participants with low (<200 ng/L) 
and high (≥ 200 ng/L) NT-proBNP levels. For participants with low NT-proBNP levels, we observed that higher 
cTnT was associated with worse cognitive function on the Stroop test, Letter-Digit Coding test, immediate 
Picture-Word Learning test and delayed Picture-Word Learning test (all p-values <0.05). Although this trend was 
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less marked on all four cognitive function tests for participants with high NT-proBNP levels, there was no 
significant difference between low and high NT-proBNP levels in the association of cTnT with cognitive function 
(all p-values for interaction >0.05). Table 3 shows the longitudinal association of cTnT with cognitive decline in 
participants with low and high NT-proBNP levels. Again, a trend was found showing that in participants with low 
NT-proBNP levels, higher levels of cTnT were associated with steeper decline on all four cognitive function 
tests. This association remained significant for the immediate Picture-Word Learning test. However, this 
difference between low and high NT-proBNP levels in the association of cTnT with cognitive function was not 
significant (all p-values for interaction > 0.05). When further adjusting for continuous levels of NT-proBNP and 
when stratifying our analyses according to the less conservative cut-off of NT-proBNP < and ≥ 400 ng/L, the 
association between cTnT and cognitive function and decline remained essentially the same (supplemental 
tables 2 and 3).  Furthermore, participants with a history of diabetes mellitus had a steeper decline in immediate 
Picture-Word learning test. In addition, the observed associations of cTnT with cognitive function and decline did 
not materially change when excluding participants with heart failure hospitalization during follow-up (n=205) and 
participants who used loop diuretics (n=588) (supplemental table 4). 
 
Furthermore, we investigated whether incident cardiovascular diseases might confound our results, by 
performing sensitivity analyses in which we separately excluded participants who, during follow-up, had 1) a 
stroke or TIA (n=378); 2) coronary events (n=575); 3) atrial fibrillation (n=507); 4) cardiovascular events 
(n=872); and finally 5) a sign of previous myocardial infarction (defined as pathological Q or QS-waves on their 
baseline ECG) (n=1211). In general, exclusion of these participants did not affect the association of cTnT with 
cognitive function and decline (supplemental tables 5 and 6). In addition, we investigated the association of 
normal values of cTnT with cognitive function and decline, by excluding participants with cTnT > 0.014 μg/L, 
conform 99th percentile (n=1002). Results from these analyses did not essentially differ (supplemental table 7).   
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Discussion 
In this large prospective cohort study, we found that among 5407 older men and women, higher levels of hs-
cTnT were associated with worse cognitive function at baseline and steeper cognitive decline. Results were 
independent of cardiovascular diseases or risk factors. Similar trends were observed in participants with lower 
NT-proBNP levels below levels which might be indicative of clinical heart failure. 
 
Our findings are in line with a previous study by Schneider et al., investigating the association of hs-cTnT with 
cognitive function.(7) This prospective follow-up study, which included 9472 community-dwelling participants 
with a mean age of 63 years, showed that higher levels of hs-cTnT were associated with lower scores on a digit 
symbol substitution test and a word fluency test, indicating worse cognitive function. Furthermore, during a 
median follow-up period of 13 years, higher baseline concentrations of hs-cTnT were associated with an 
increased risk for dementia hospitalizations.(7) Although these results did not appreciably alter when analyses 
were additionally adjusted for left ventricular hypertrophy and carotid intima media thickness, no information on 
NT-proBNP was available. In addition, this study did not consider apolipoprotein E4 genotype, a well-known risk 
factor for the development of cognitive impairment, as a potential confounder in the association between hs-
cTnT and cognitive function.(18) Another difference between the present study and the study by Schneider et al. 
was the cognitive test battery. Both studies used measures of delayed word memory and the digit symbol 
substitution test, which measures processing speed and executive function. The only difference is that the ARIC 
study used the Word Fluency Test, whereas we used the Stroop test, although both measure executive function 
and processing speed. We think it is unlikely that this difference in choice of tests is significant enough to make 
different inferences about the outcome. To our knowledge, our study is the first examining the association of hs-
cTnT and cognitive function in older adults at high cardiovascular risk, which tested the potential role of 
cardiovascular diseases, risk factors and NT-proBNP, and adjusted for apolipoprotein E4 genotype as well. 
 
Several mechanisms can be proposed to explain the association of cTnT with worse cognitive function and 
steeper cognitive decline. First, cTnT might be a reflection of underlying myocardial injury as well as cerebral 
damage, rather than being causally related. It is well known that cardiovascular and cerebrovascular disease 
share the same risk factors, including hypertension, diabetes mellitus and smoking. These risk factors for 
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cognitive decline clearly also cause myocardial disease, resulting in increased levels of cTnT. The finding that 
participants with a history of hypertension and diabetes mellitus had a steeper decline on Picture-Word 
immediate test in stratified analyses, further supports this hypothesis. Second, although our results were found 
in participants without NYHA functional class stage III or IV, we do not have echocardiography data to rule out 
the possibility that higher levels of cTnT indicate suboptimal cardiac functioning with subsequent decreased 
cardiac output and cerebral hypoperfusion.(19, 20) Cerebral hypoperfusion has previously been associated with 
a higher risk of dementia.(21) However, this explanation is less likely since in the current study, participants with 
NT-proBNP levels <200 ng/L showed the same results, and additional adjustment for NT-proBNP levels did not 
change the results. Third, cTnT might have a direct effect in the brain, causing decreased cerebral function. 
However, no evidence has been provided for this explanation yet. Fourth, although it is generally believed that 
cTnT is only expressed in striated muscle cells, animal studies have revealed expression of troponin proteins, 
including troponin T, in smooth muscle cells of rats and mice as well.(22, 23) In addition, a recent report has 
shown the existence of cTnT in vascular smooth muscle cells of humans, and also found that cTnT contributes 
to calcium-mediated contraction of smooth muscle cells in mice experiments.(24) Although it has been reported 
that cTnT is highly specific for cardiomyocytes, these recent findings suggest that cTnT might also be a 
reflection of smooth muscle cell involvement.(24) Higher levels of cTnT may therefore indicate vascular smooth 
muscle cell damage in an early stage, before the manifestation of clinical or even subclinical diseases. This 
might also explain the observation that higher levels of cTnT are associated with subclinical brain disease, 
including silent brain infarcts and white matter hyperintensities.(5) Speculatively, cTnT is not only released by 
cardiomyocytes but also by smooth muscle cells in the brain vasculature, and may therefore mark structural 
brain damage as a cause of cognitive decline.   
 
The magnitude of the association between cTNT and cognitive decline we report, is comparable in magnitude to 
associations of known risk factors of cognitive decline, such as APOE4 carriership, smoking status and history 
of diabetes, indicating that the effects are clinically relevant. 
 
A limitation of this study might be that all participants had cardiovascular diseases or risk factors thereof, which 
might restrict the extrapolation of our findings to a general population of older individuals. However, at the same 
time this is an advantage of our study, since it allows us to perform several sensitivity analyses to investigate 
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the influence of cardiovascular diseases and risk factors on the association between cTnT and cognitive 
function. Second, although we adjusted our analyses for potential confounders, it is uncertain if this fully 
accounts for the differences between the troponin groups. In addition, there might still be other factors which we 
did not consider in our analyses. Furthermore, the lack of extensive information on cardiac functioning is a 
weakness of our study. Strength of this study is the large sample size of 5407 participants, who all underwent 
repeated extensive neuropsychological examination including four different cognitive function tests, during a 
mean follow-up period of 3.2 years, and, critically, inclusion and adjustment for NTproBNP measures. 
Furthermore, cTnT measurements were performed using a high-sensitivity assay, which can detect 10-fold 
lower concentrations than the usual assay, and therefore allows detection of already very minor damage of the 
myocardial tissue.  
 
Higher levels of hs-cTnT associate with worse cognitive function and steeper cognitive decline in older adults 
independent of cardiovascular diseases and risk factors and NT-proBNP.   
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Abbreviations: SD, standard deviation; n, number; TIA, transient ischemic attack; eGFR, estimated glomerular filtration rate; NT-proBNP, N-terminal pro-brain 
natriuretic peptide.  
P-values were calculated using the continuous value of the square root of troponin levels for continuous variables and Chi-squared tests for categorical 
variables.         
*adjusted p-value for age and sex  #measured at 6 months    ^missing data for n=716 participants. 
 
 
 
 
Table 1 Baseline characteristics of study participants by thirds of cardiac troponin T 
 Thirds of cardiac troponin T P-value 
 
 
Low 
0.002-0.004 μg/L 
N=1584 
 Middle 
0.005-0.009 μg/L 
N=1972 
 High 
0.010-1.840 μg/L 
N=1851 
  
Demographics        
  Age (years), mean (SD) 74.37 (3.18)  75.17 (3.11)  76.27 (3.44)  <0.001 
  Female, n (%) 1114 (70.3)  977 (49.5)  693 (37.4)  <0.001 
  Education (age left school), mean (SD) 15.14 (1.99)  15.16 (2.22)  15.12 (2.15)  0.829 
Pravastatin treatment, n (%) 778 (49.1)  983 (49.8)  921 (49.8)  0.898 
Vascular risk factors        
  History of hypertension, n (%) 952 (60.2)  1202 (61.0)  1199 (64.8)  0.011 
  History of diabetes mellitus, n (%) 120 (7.6)  209 (10.6)  247 (13.3)  <0.001 
  History of stroke or TIA, n (%) 147 (9.3)  207 (10.5)  248 (13.4)  <0.001 
  History of myocardial infarction, n (%) 140 (8.8)  252 (12.8)  330 (17.8)  <0.001 
  History of vascular disease, n (%) 620 (39.1)  861 (43.7)  916 (49.5)  <0.001 
  Current smoker, n (%) 451 (28.5)  535 (27.1)  441 (23.8)  0.006 
  Body mass index (kg/m2), mean (SD)* 26.12 (4.38)  26.82 (4.00)  27.41 (4.30)  <0.001 
  Total cholesterol (mmol/L), mean (SD)* 5.71 (0.80)  5.65 (0.89)  5.66 (0.86)  0.112 
  High density lipoprotein* (mmol/L), mean (SD) 1.29 (0.40)  1.28 (0.44)  1.27 (0.43)  0.404 
  Low density lipoprotein* (mmol/L), mean (SD) 3.83 (0.80)  3.76 (0.89)  3.77 (0.86)  0.083 
  Systolic blood pressure (mmHg), mean (SD)* 151.17 (22.29)  155.11 (21.32)  157.39 (22.37)  <0.001 
  Diastolic blood pressure (mmHg), mean (SD)* 82.76 (11.94)  84.02 (11.55)  84.44 (11.62)  <0.001 
Blood pressure lowering medication, n (%)        
   Diuretics 572 (36.1)  755 (38.3)  851 (46.0)  <0.001 
   ACE-inhibitors 185 (11.7)  292 (14.8)  409 (22.1)  <0.001 
   Beta-blockers 408 (25.8)  523 (26.5)  462 (25.0)  0.544 
   Calcium channel blockers 413 (26.1)  475 (24.1)  476 (25.7)  0.334 
ApoE genotype       0.783 
   E2 carriers 14 (0.9)  12 (0.6)  9 (0.5)   
   E3/E3 carries 984 (62.1)  1226 (62.2)  1123 (60.7)   
   E4 carriers 389 (24.6)  482 (24.4)  452 (24.4)   
Biochemistry, mean (SD)        
  eGFR (ml/min/m1.73m2) 61.07 (14.33)  60.86 (14.65)  58.24 (14.63)  <0.001 
  NT-proBNP level (ng/L)* # 159.39 (549.23)  230.77 (525.78)  475.51 (542.09)  <0.001 
  Fasting glucose level (mmol/L)*^ 5.41 (1.49)  5.45 (1.25)  5.49 (1.58)  0.362 
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Table 2 Association of cardiac troponin T with cognitive function at baseline and during follow-up 
  Thirds of cardiac troponin T  P-value* 
 
 
Cognitive tests (mean, SE) 
 Low 
0.002-0.004 μg/L 
 Middle 
0.005-0.009 μg/L 
 High 
0.010-1.840 μg/L 
  
Stroop, seconds Baseline score 65.91 (1.16)  67.26 (1.10)  70.09 (1.10)  <0.001 
 Annual change 0.34 (0.12)  0.59 (0.11)  1.06 (0.12)  0.013 
         
LDCT, digits coded Baseline score 23.36 (0.32)  22.94 (0.30)  22.28 (0.30)  <0.001 
 Annual change -0.29 (0.03)  -0.34 (0.02)  -0.46 (0.03)  <0.001 
         
PLTi, pictures remembered Baseline score 9.45 (0.09)  9.36 (0.08)  9.28 (0.08)  0.002 
 Annual change 0.01 (0.01)  -0.02 (0.01)  -0.06 (0.01)  <0.001 
         
PLTd, pictures remembered Baseline score 10.31 (0.12)  10.09 (0.12)  10.05 (0.11)  0.013 
 Annual change -0.03 (0.01)  -0.06 (0.01)  -0.12 (0.02)  0.001 
         
Data represent model-based adjusted means (standard error) of each cognitive function test concerning the baseline associations. For the longitudinal analyses, data represent model-based adjusted mean annual 
change (standard error) per 1 square root (ng/L) increase of cardiac troponin T for each cognitive function test. Cardiac troponin T was measured after  6 months of follow-up. 
*Adjusted p-values were calculated using the continuous value of the square root of troponin levels. 
Abbreviations: SE, standard error; LDCT, Letter-Digit Coding  test; PLTi, Picture-Word Learning test, immediate; PLTd, Picture-Word Learning test, delayed. 
Data are adjusted for age, sex, country, education, treatment group, test version for LDCT and PLT, ApoE genotype, history of vascular disease, history of hypertension, history of diabetes mellitus, current smoking, 
baseline systolic and diastolic blood pressure, HDL and LDL cholesterol, triglycerides, body mass index, eGFR.  
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Table 3 Association of cardiac troponin T and NT-proBNP with cognitive decline during follow-up 
 Thirds of cardiac troponin T  P-value* 
 
 
 
NT-proBNP 
 
Low 
0.002-0.004 μg/L 
  
Middle 
0.005-0.009 μg/L 
  
High 
0.010-1.840 μg/L 
  
Low (<200 ng/L) N=1254  N=1279  N=826   
 Stroop, seconds 0.27 (0.13)  0.64 (0.13)  0.71 (0.17)  0.076 
 LDCT, digits coded -0.27 (0.03)  -0.34 (0.03)  -0.38 (0.04)  0.287 
 PLTi, pictures remembered 0.01 (0.01)  -0.01 (0.01)  -0.05 (0.02)  0.001 
 PLTd, pictures remembered -0.02 (0.02)  -0.06 (0.02)  -0.09 (0.02)  0.176 
 
High (≥ 200 ng/L) 
 
N=330 
  
N=693 
  
N=1025 
  
 Stroop, seconds 0.59 (0.29)  0.45 (0.21)  1.48 (0.19)  0.540 
 LDCT, digits coded -0.37 (0.06)  -0.34 (0.04)  -0.53 (0.04)  0.001 
 PLTi, pictures remembered 0.01 (0.02)  -0.04 (0.02)  -0.07 (0.02)  0.070 
 PLTd, pictures remembered -0.06 (0.04)  -0.06 (0.03)  -0.14 (0.02)  0.120 
Abbreviations: SE, standard error; n, number; LDCT, Letter-Digit Coding test; PLTi, Picture-Word Learning test, immediate; PLTd, Picture-Word Learning test, delayed. 
Data represent model-based adjusted mean annual change (standard error) per 1 square root (ng/L) increase of cardiac troponin T for each cognitive function test. Cardiac troponin T and NT-proBNP were 
measured after 6 months of follow-up. 
*Adjusted p-values were calculated using the interaction term of time x square root of troponin levels. 
Adjusted for age, sex, country, education, treatment group, test version for LDCT and PLT, ApoE genotype, history of cerebrovascular and cardiovascular disease, history of hypertension, history of diabetes 
mellitus, current smoking, baseline systolic and diastolic blood pressure, HDL and LDL cholesterol, triglycerides, body mass index and eGFR. 
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Figure 1 Association of cardiac troponin T with cognitive decline during follow-up, stratified by 
cardiovascular diseases and risk factors 
 
Legend: Data represent mean annual change (95% confidence interval) per 1 square root (ng/L) increase of cardiac troponin T for each cognitive test, stratified by 
cardiovascular diseases. Higher annual change indicates less decline in cognitive function over time; expect for the Stroop test, where higher annual change means 
more decline in cognitive function over time. P-values were calculated using the interaction term of cardiovascular disease, square root of cardiac troponin T, and 
time. They represent the statistical difference in annual change in cognitive function between participants with and without cardiovascular disease or risk factors. 
Adjusted for age, sex, country, education, treatment group and test version where appropriate.  
 
 22 
Figure 2 Association of cardiac troponin T with baseline cognitive function, stratified by NT-proBNP 
 
Legend: Abbreviations: SE, standard error. Adjusted for age, sex, country, education, treatment group, test version for LDCT and PLT, ApoE genotype, history of 
cerebrovascular and cardiovascular disease, history of hypertension, history of diabetes mellitus, current smoking, baseline systolic and diastolic blood pressure, 
HDL and LDL cholesterol, triglycerides, body mass index and eGFR. Higher scores indicate better cognitive performance; expect for the Stroop test, where a higher 
score indicates worse performance.        
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Supplemental table 1 Association of cardiac troponin T with cognitive function at baseline and during follow-up 
(minimally adjusted models) 
 Thirds of cardiac troponin T  P-value* 
Cognitive tests (mean, SE) 
 
 Low 
0.002-0.004 μg/L 
 Middle 
0.005-0.009 μg/L 
 High 
0.010-1.840 μg/L 
  
Stroop, seconds Baseline score 63.06 (0.65)  64.44 (0.56)  67.30 (0.61)  <0.001 
 Annual change 0.34 (0.12)  0.58 (0.11)  1.05 (0.12)  0.015 
         
LDCT, digits coded Baseline score 24.18 (0.18)  23.77 (0.15)  23.17 (0.17)  <0.001 
 Annual change -0.29 (0.03)  -0.34 (0.02)  -0.46 (0.03)  <0.001 
         
PLTi, pictures remembered Baseline score 9.56 (0.05)  9.47 (0.04)  9.39 (0.04)  0.001 
 Annual change 0.01 (0.01)  -0.02 (0.01)  -0.06 (0.01)  <0.001 
         
PLTd, pictures remembered Baseline score 10.50 (0.07)  10.26 (0.06)  10.22 (0.06)  0.004 
 Annual change -0.03 (0.02)  -0.06 (0.02)  -0.12 (0.02)  0.001 
         
Abbreviations: SE, standard error; LDCT, Letter-Digit Coding  test; PLTi, Picture-Word Learning test, immediate; PLTd, Picture-Word Learning test, delayed. Data represent model-based adjusted means 
(standard error) of each cognitive function test concerning the baseline associations. For the longitudinal analyses, data represent model-based adjusted mean annual change (standard error) per 1 square root 
(ng/L) increase of cardiac troponin T for each cognitive function test. Cardiac troponin T was measured after  6 months of follow-up. Data are adjusted for age, sex, country, education, treatment group, test 
version for LDCT and PLT. *Adjusted p-values were calculated using the continuous value of the square root of troponin levels. 
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Supplemental table 2 Association of cardiac troponin T with cognitive function at baseline and during follow-up, 
additionally adjusted for NT-proBNP 
  Thirds of cardiac troponin T  P-value* 
 
 
Cognitive tests (mean, SE) 
 Low 
0.002-0.004 μg/L 
 Middle 
0.005-0.009 μg/L 
 High 
0.010-1.840 μg/L 
  
Stroop, seconds Baseline score 66.22 (1.16)  67.38 (1.10)  69.43 (1.11)  0.013 
 Annual change 0.34 (0.12)  0.59 (0.11)  1.07 (0.12)  0.010 
         
LDCT, digits coded Baseline score 23.32 (0.32)  22.92 (0.30)  22.37 (0.30)  <0.001 
 Annual change -0.29 (0.03)  -0.34 (0.02)  -0.47 (0.03)  <0.001 
         
PLTi, pictures remembered Baseline score 9.44 (0.09)  9.36 (0.08)  9.28 (0.08)  0.005 
 Annual change 0.01 (0.01)  -0.02 (0.01)  -0.06 (0.01)  <0.001 
         
PLTd, pictures remembered Baseline score 10.30 (0.12)  10.09 (0.12)  10.06 (0.12)  0.041 
 Annual change -0.03 (0.02)  -0.06 (0.01)  -0.12 (0.02)  0.001 
         
Abbreviations: SE, standard error; LDCT, Letter-Digit Coding  test; PLTi, Picture-Word Learning test, immediate; PLTd, Picture-Word Learning test, delayed. Data represent model-based adjusted means 
(standard error) of each cognitive function test concerning the baseline associations. For the longitudinal analyses, data represent model-based adjusted mean annual change (standard error) per 1 square root 
(ng/L) increase of cardiac troponin T for each cognitive function test. Cardiac troponin T was measured after  6 months of follow-up. Data are adjusted for age, sex, country, education, treatment group, test 
version for LDCT and PLT, ApoE genotype, history of vascular disease, history of hypertension, history of diabetes mellitus, current smoking, baseline systolic and diastolic blood pressure, HDL and LDL 
cholesterol, triglycerides, body mass index, eGFR and NT-proBNP level. *Adjusted p-values were calculated using the continuous value of the square root of troponin levels. 
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Supplemental table 3 Association of cardiac troponin T and NT-proBNP with cognitive function at baseline and during 
follow-up (stratified by NT-proBNP < and ≥ 400 ng/L) 
  Thirds of cardiac troponin T  P-value* 
 
 
Cognitive tests (mean, SE) 
 Low 
0.002-0.004 μg/L 
 Middle 
0.005-0.009 μg/L 
 High 
0.010-1.840 μg/L 
  
NT-proBNP < 400 ng/L  N=1496  N=1713  N=1265   
Stroop, seconds Baseline score 64.75 (1.20)  65.99 (1.15)  68.55 (1.19)  <0.001 
 Annual change 0.33 (0.12)  0.60 (0.11)  0.85 (0.14)  0.130 
LDCT, digits coded Baseline score 23.67 (0.34)  23.27 (0.33)  22.71 (0.34)  <0.001 
 Annual change -0.28 (0.03)  -0.33 (0.03)  -0.43 (0.03)  0.085 
PLTi, pictures remembered Baseline score 9.54 (0.09)  9.43 (0.09)  9.38 (0.09)  0.006 
 Annual change -0.23 (0.11)  -0.08 (0.08)  -0.13 (0.05)  0.001 
PLTd, pictures remembered Baseline score 10.43 (0.13)  10.17 (0.13)  10.22 (0.13)  0.016 
 Annual change -0.03 (0.02)  -0.05 (0.02)  -0.10 (0.02)  0.042 
         
NT-proBNP ≥ 400 ng/L  N=88  N=259  N=586   
Stroop, seconds Baseline score 73.81 (4.28)  75.94 (3.37)  76.56 (3.05)  0.291 
 Annual change 0.40 (0.69)  0.37 (0.43)  1.79 (0.30)  0.744 
LDCT, digits coded Baseline score 20.83 (0.98)  20.97 (0.76)  20.47 (0.69)  0.054 
 Annual change -0.37 (0.12)  -0.38 (0.07)  -0.53 (0.05)  0.004 
PLTi, pictures remembered Baseline score 8.76 (0.27)  9.02 (0.21)  8.82 (0.19)  0.395 
 Annual change 0.10 (0.05)  -0.06 (0.03)  -0.09 (0.02)  0.126 
PLTd, pictures remembered Baseline score 9.81 (0.37)  9.72 (0.29)  9.36 (0.26)  0.372 
 Annual change 0.01 (0.08)  -0.10 (0.05)  -0.17 (0.03)  0.445 
Abbreviations: SE, standard error; LDCT, Letter-Digit Coding  test; PLTi, Picture-Word Learning test, immediate; PLTd, Picture-Word Learning test, delayed. Data represent model-based adjusted means 
(standard error) of each cognitive function test concerning the baseline associations. For the longitudinal analyses, data represent model-based adjusted mean annual change (standard error) per 1 square root 
(ng/L) increase of cardiac troponin T for each cognitive function test. Cardiac troponin T was measured after  6 months of follow-up. Data are adjusted for age, sex, country, education, treatment group, test 
version for LDCT and PLT, ApoE genotype, history of vascular disease, history of hypertension, history of diabetes mellitus, current smoking, baseline systolic and diastolic blood pressure, HDL and LDL 
cholesterol, triglycerides, body mass index, eGFR. *Adjusted p-values were calculated using the continuous value of the square root of troponin levels. 
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Supplemental table 4 Association of cardiac troponin T with cognitive function at baseline and during follow-up 
(participants with heart failure hospitalization (n=205) and participants using loop diuretics (n=588) excluded) 
  Thirds of cardiac troponin T  P-value* 
 
 
Cognitive tests (mean, SE) 
 Low 
0.002-0.004 μg/L 
 Middle 
0.005-0.009 μg/L 
 High 
0.010-1.840 μg/L 
  
Stroop, seconds Baseline score 65.33 (1.22)  67.09 (1.17)  68.11 (1.19)  <0.001 
 Annual change 0.37 (0.13)  0.55 (0.12)  1.00 (0.13)  <0.001 
         
LDCT, digits coded Baseline score 23.38 (0.34)  22.96 (0.33)  22.46 (0.33)  <0.001 
 Annual change -0.30 (0.03)  -0.33 (0.03)  -0.45 (0.03)  <0.001 
         
PLTi, pictures remembered Baseline score 9.51 (0.09)  9.44 (0.09)  9.39 (0.09)  0.028 
 Annual change 0.02 (0.01)  -0.02 (0.01)  -0.05 (0.01)  <0.001 
         
PLTd, pictures remembered Baseline score 10.37 (0.13)  10.20 (0.13)  10.22 (0.13)  0.051 
 Annual change -0.02 (0.02)  -0.06 (0.02)  -0.11 (0.02)  <0.001 
         
Abbreviations: SE, standard error; LDCT, Letter-Digit Coding  test; PLTi, Picture-Word Learning test, immediate; PLTd, Picture-Word Learning test, delayed. Data represent model-based adjusted means 
(standard error) of each cognitive function test concerning the baseline associations. For the longitudinal analyses, data represent model-based adjusted mean annual change (standard error) per 1 square root 
(ng/L) increase of cardiac troponin T for each cognitive function test. Data are adjusted for age, sex, country, education, treatment group, test version for LDCT and PLT, ApoE genotype, history of vascular 
disease, history of hypertension, history of diabetes mellitus, current smoking, baseline systolic and diastolic blood pressure, HDL and LDL cholesterol, triglycerides, body mass index, eGFR. *Adjusted p-values 
were calculated using the continuous value of the square root of troponin levels. 
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Supplemental table 5 Association of cardiac troponin T with baseline cognitive function 
 Thirds of cardiac troponin T  P-value* 
 
Cognitive tests (mean, SE) 
Low 
0.002-0.004 μg/L 
 Middle 
0.005-0.009 μg/L 
 High 
0.010-1.840 μg/L 
  
Exclusion of participants with stroke/tia (N=378) N=1497  N=1838  N=1694   
Stroop, seconds 65.19 (1.21)  66.97 (1.15)  69.68 (1.15)  <0.001 
LDCT, digits coded 23.52 (0.33)  23.01 (0.31)  22.30 (0.31)  <0.001 
PLTi, pictures remembered 9.48 (0.09)  9.41 (0.08)  9.31 (0.08)  0.001 
PLTd, pictures remembered 10.36 (0.13)  10.15 (0.12)  10.10 (0.12)  0.014 
Exclusion of participants with coronary events (N=575) N=1495  N=1809  N=1528   
Stroop, seconds 65.44 (1.18)  66.96 (1.12)  69.08 (1.13)  <0.001 
LDCT, digits coded 23.62 (0.34)  23.19 (0.32)  22.55 (0.32)  <0.001 
PLTi, pictures remembered 9.44 (0.09)  9.36 (0.09)  9.27 (0.09)  0.015 
PLTd, pictures remembered 10.33 (0.13)  10.07 (0.12)  10.05 (0.12)  0.008 
Exclusion of participants with AF (N=507) N=1507  N=1814  N=1579   
Stroop, seconds 65.32 (1.21)  66.79 (1.15)  69.46 (1.16)  <0.001 
LDCT, digits coded 23.38 (0.34)  22.97 (0.32)  22.44 (0.32)  <0.001 
PLTi, pictures remembered 9.44 (0.09)  9.38 (0.09)  9.26 (0.09)  0.005 
PLTd, pictures remembered 10.29 (0.13)  10.13 (0.12)  10.04 (0.12)  0.042 
Exclusion of participants with cardiovascular events (N=872) N=1421  N=1694  N=1420   
Stroop, seconds 64.36 (1.22)  66.20 (1.16)  68.10 (1.17)  <0.001 
LDCT, digits coded 23.76 (0.35)  23.33 (0.33)  22.64 (0.33)  <0.001 
PLTi, pictures remembered 9.50 (0.09)  9.41 (0.09)  9.34 (0.09)  0.037 
PLTd, pictures remembered 10.37 (0.13)  10.13 (0.13)  10.11 (0.13)  0.035 
Exclusion of participants with path. Q waves (N=1211) N=1339  N=1513  N=1344   
Stroop, seconds 65.98 (1.26)  67.14 (1.20)  68.54 (1.22)  0.144 
LDCT, digits coded 23.41 (0.36)  23.16 (0.34)  22.76 (0.34)  0.005 
PLTi, pictures remembered 9.44 (0.10)  9.38 (0.09)  9.30 (0.09)  0.029 
PLTd, pictures remembered 10.32 (0.13)  10.12 (0.13)  10.10 (0.13)  0.080 
Abbreviations: SE, standard error; LDCT, Letter-Digit Coding  test; PLTi, Picture-Word Learning test, immediate; PLTd, Picture-Word Learning test, delayed. Data represent model-based adjusted means 
(standard error) of each cognitive function test. Analyses were adjusted for sex, age, country, education, treatment code, test version for LDCT and PLT, ApoE genotype, history of vascular disease, history of 
hypertension, history of diabetes mellitus, current smoking, baseline systolic and diastolic blood pressure, HDL and LDL cholesterol, triglycerides, body mass index and eGFR. *Adjusted p-values were 
calculated using the continuous value of the square root of troponin levels. 
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Supplemental table 6 Association of cardiac troponin T with cognitive decline during follow-up 
 Thirds of cardiac troponin T  P-value* 
 
Cognitive tests (mean, SE) 
Low 
0.002-0.004 μg/L 
 Middle 
0.005-0.009 μg/L 
 High 
0.010-1.840 μg/L 
  
Exclusion of participants with stroke/tia (N=378)        
Stroop, seconds 0.26 (0.12)  0.47 (0.11)  0.93 (0.12)  0.033 
LDCT, digits coded -0.27 (0.03)  -0.31 (0.02)  -0.42 (0.03)  <0.001 
PLTi, pictures remembered 0.02 (0.01)  -0.02 (0.01)  -0.05 (0.01)  <0.001 
PLTd, pictures remembered -0.02 (0.02)  -0.06 (0.01)  -0.11 (0.02)  0.002 
Exclusion of participants with coronary events (N=575)        
Stroop, seconds 0.28 (0.12)  0.58 (0.11)  0.98 (0.13)  0.040 
LDCT, digits coded -0.28 (0.03)  -0.35 (0.03)  -0.44 (0.03)  0.003 
PLTi, pictures remembered 0.01 (0.01)  -0.02 (0.01)  -0.06 (0.01)  <0.001 
PLTd, pictures remembered -0.03 (0.02)  -0.06 (0.02)  -0.11 (0.02)  0.018 
Exclusion of participants with AF (N=507)        
Stroop, seconds 0.31 (0.12)  0.53 (0.11)  0.96 (0.13)  0.042 
LDCT, digits coded -0.29 (0.03)  -0.31 (0.03)  -0.45 (0.03)  <0.001 
PLTi, pictures remembered 0.01 (0.01)  -0.02 (0.01)  -0.04 (0.01)  <0.001 
PLTd, pictures remembered -0.02 (0.02)  -0.05 (0.01)  -0.10 (0.02)  0.002 
Exclusion of participants with cardiovascular events (N=872)        
Stroop, seconds 0.24 (0.12)  0.47 (0.11)  0.83 (0.13)  0.129 
LDCT, digits coded -0.26 (0.03)  -0.32 (0.03)  -0.41 (0.03)  0.003 
PLTi, pictures remembered 0.02 (0.01)  -0.01 (0.01)  -0.06 (0.01)  <0.001 
PLTd, pictures remembered -0.02 (0.02)  -0.05 (0.02)  -0.10 (0.02)  0.008 
Exclusion of participants with path. Q waves (N=1211)        
Stroop, seconds 0.32 (0.13)  0.55 (0.12)  1.09 (0.14)  0.005 
LDCT, digits coded -0.29 (0.03)  -0.36 (0.03)  -0.46 (0.03)  <0.001 
PLTi, pictures remembered 0.01 (0.01)  -0.02 (0.01)  -0.05 (0.01)  <0.001 
PLTd, pictures remembered -0.03 (0.02)  -0.05 (0.02)  -0.12 (0.02)  0.003 
Abbreviations: SE, standard error; LDCT, Letter-Digit Coding test; PLTi, Picture-Word Learning test, immediate; PLTd, Picture-Word Learning test, delayed. Data represent model-based adjusted mean annual 
change (standard error) per 1 square root (ng/L) increase of cardiac troponin T for each cognitive function test. Adjusted for age, sex, country, education, treatment group, test version for LDCT and PLT, ApoE 
genotype, history of cerebrovascular and cardiovascular disease, history of hypertension, history of diabetes mellitus, current smoking, baseline systolic and diastolic blood pressure, HDL and LDL cholesterol, 
triglycerides, body mass index and eGFR. *Adjusted p-values were calculated using the interaction term of time x square root of troponin levels. 
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Supplemental table 7 Association of cardiac troponin T with cognitive function at baseline and during follow-up 
(exclusion of participants with cTnT >0.014 μg/L) 
  Thirds of cardiac troponin T  P-value* 
 
 
Cognitive tests (mean, SE) 
 Low 
0.002-0.004 μg/L 
N=1584 
 Middle 
0.005-0.009 μg/L 
N=1972 
 High 
0.010-0.013 μg/L 
N=849 
  
Stroop, seconds Baseline score 65.04 (0.40)  66.80 (0.38)  68.03 (0.43)  0.001 
 Annual change 0.34 (0.12)  0.59 (0.11)  1.18 (0.17)  <0.001 
         
LDCT, digits coded Baseline score 23.46 (0.11)  23.02 (0.11)  22.86 (0.12)  0.002 
 Annual change -0.29 (0.03)  -0.34 (0.02)  -0.43 (0.04)  0.003 
         
PLTi, pictures remembered Baseline score 9.45 (0.03)  9.37 (0.03)  9.33 (0.03)  0.033 
 Annual change 0.01 (0.01)  -0.02 (0.01)  -0.04 (0.02)  <0.001 
         
PLTd, pictures remembered Baseline score 10.35 (0.04)  10.12 (0.04)  10.12 (0.05)  0.002 
 Annual change -0.03 (0.02)  -0.06 (0.01)  -0.10 (0.02)  0.016 
         
Abbreviations: SE, standard error; LDCT, Letter-Digit Coding  test; PLTi, Picture-Word Learning test, immediate; PLTd, Picture-Word Learning test, delayed. Data represent model-based adjusted means 
(standard error) of each cognitive function test concerning the baseline associations. For the longitudinal analyses, data represent model-based adjusted mean annual change (standard error) per 1 square root 
(ng/L) increase of cardiac troponin T for each cognitive function test. Data are adjusted for age, sex, country, education, treatment group, test version for LDCT and PLT, ApoE genotype, history of vascular 
disease, history of hypertension, history of diabetes mellitus, current smoking, baseline systolic and diastolic blood pressure, HDL and LDL cholesterol, triglycerides, body mass index, eGFR. *Adjusted p-values 
were calculated using the interaction term of time x square root of troponin levels. 
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Supplemental figure 1 
 
 
 
Cardiac troponin T measurement (6 months) 
High 
0.010-1.840 μg/L 
N=1851 
Exclusion: 
N= 397 participants with missing cTnT 
measurements 
PROSPER randomization  
N=5804 
N=5407 
Middle 
0.005-0.009 μg/L 
N=1972 
Low 
0.002-0.004 μg/L 
N=1584 
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Supplemental figure 2 Distribution of hs-cTnT levels 
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